Plain Language Summaries of research results

Patients are at the center of everything we do at UCB. Helping patients, caregivers, and the public understand the results of research is essential to that mission.


In 2014, UCB began posting lay summaries of clinical study results to our website. Currently, these summaries are posted for at least the pivotal and key studies of approved or withdrawn medicines. For each summary, we include feedback from a panel that includes a patient, caregiver, medical professional, lay expert, and member of the general public to make sure the summary is understandable.

Kenichiro-living-with-RA

UCB’s Policy for Plain Language Summaries is:

Studies that begun after 31 January 2022

UCB will publicly post Plain Language Summaries on UCB.com that were written according to regulatory requirements after the product and indication are authorized for marketing.

document_icon_light_blue_200x200.png
stopwatch_icon_light_blue_S.png
  • For Phase 1-4 clinical studies in a pediatric population and/or part of a Pediatric Investigational Plan, Plain Language Summaries will be posted and published on CTIS within 6 months after the global Last Patient Last Visit (LPLV)
  • For Phase 1 clinical studies in adult populations, Plain Language Summaries will be posted on CTIS within 12 months after the global LPLV and published within 30 months after the global LPLV.
  • For Phase 2-4  clinical studies in adult population, Plain Language Summaries will be posted and published on CTIS within 12 months after the global LPLV.
To our lay summaries

 

[1] For this policy, observational studies refer to real-world evidence studies that compare the effectiveness or safety of two drugs (including at least one UCB product) using a hypothesis.